Moreover, in studies involving NUP98-NSD1+ AML, the use of EZH2 enzymatic inhibitors demonstrated that tumorigenicity was dependent on PRC2/EZH2 (Ren et al., 2022). This evidence concerns the gene EZH2 and acute myeloid leukemia.